CDK4 and CDK6 kinases: From basic science to cancer therapy.

Area of Science:

• Oncology
• Molecular Biology
• Cell Cycle Regulation

Background:

• Cyclin-dependent kinases 4 and 6 (CDK4/6) and D-type cyclins regulate cell cycle progression.
• Constitutive activation of cyclin D–CDK4/6 is a key driver in multiple cancers.
• CDK4/6 inhibitors are established treatments for hormone receptor-positive breast cancer.

Purpose of the Study:

• To review recent findings on CDK4/6 biology beyond cell cycle control.
• To explore the impact of CDK4/6 inhibition on tumor cell metabolism and immunity.
• To discuss novel therapeutic strategies for CDK4/6 inhibitors in cancer treatment.

Main Methods:

• Literature review of recent studies on CDK4/6 inhibitors.
• Analysis of data on cellular functions affected by CDK4/6 inhibition.
• Synthesis of information on emerging therapeutic applications.

Main Results:

• CDK4/6 inhibition influences tumor cell metabolism.
• CDK4/6 inhibition modulates antitumor immunity.
• These effects suggest expanded roles for CDK4/6 inhibitors.

Conclusions:

• Recent advances deepen the understanding of CDK4/6 biology.
• CDK4/6 inhibitors show promise beyond their established indications.
• New therapeutic avenues are emerging for CDK4/6 inhibitor utilization in oncology.